Fig 1&2.prism

Figure 1. Dynamics of antibody responses to ProC6C constituent antigens. Antibody reactivity to the ProC6C constituent antigens, Pfs230-Pro and Pfs48/45-6C, in individuals immunized with ProC6C-AlOH/Matrix-M (G2D, geometric mean titer, GMT-blue line) or a control vaccine (G2E, GMT-black line) at each study time point (D0, D14, D42, D70, D140, and D180). GMT is indicated in Table 1.

Figure 2. Biological activity of antibodies. Significant TRA denoted by a closed circles and non-significant TRA by open circles. A) The biological activity (functionality) for the ProC6C-AlOH/Matrix-M (G2D) and control group (G2E) is plotted for each volunteer at D70 and D180 from purified IgG at 15 mg/mL in the SMFA (with human complement) as TRA. The median for each group is indicated by a line and p values were determined by Mann Whitney test. Paired aligned dot plots showing the anti-Pfs48/45-6C (B) and anti-Pfs230-Pro (C) antibody levels at D70 and D180. Individuals were categorized into 3 subgroups based on their TRA levels: “a” significant TRA at both time points; “b” significant TRA at D70 only; and “c” insignificant TRA at both timepoints. Pairwise comparisons were performed using the Paired t test (log-transformed ELISA titers were used for all analyses) D) Pfs48/45-6C IgG concentrations TB31F equivalence (μg/mL) at D70 and D180 for each subgroup (“+” significant TRA and “-“ non-significant TRA). GMT indicated by horizontal line. TB31F threshold of 2.1 mg/mL indicated by red hashed line. Unpaired t-tests were utilized. E) Pfs230-Pro IgG arbitrary units (a.u.) at D70 and D180 for each subgroup (“+” significant TRA and “-“ non-significant TRA). GMT indicated by horizontal line. Unpaired t-tests were utilized; **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns p> 0.05.